FDA Issues MDO Orders for Over 6,500 E-Cigarette Products

May.15.2023
FDA Issues MDO Orders for Over 6,500 E-Cigarette Products
FDA issued marketing denial orders to 10 companies, preventing them from selling about 6,500 flavored e-cigarette products in the US.

On May 12th, the US Food and Drug Administration (FDA) issued marketing denial orders (MDOs) to 10 companies, all of which produced and sold approximately 6,500 flavors of e-cigarette oil and vape products. The MDOs prohibit these companies from marketing or distributing these products in the US, and retailers selling these illegal products will face enforcement actions from the FDA.


The tobacco products they submitted for pre-market tobacco product applications (PMTA) included a variety of flavored e-cigarette products, but they failed to provide sufficient evidence that allowing the sale of these products would meet public health protection requirements. The flavors of the products that were denied included citrus, strawberry cheesecake, cool mint, and mint.


Today's actions furthered the FDA's continued progress in reviewing and making decisions on over 26 million new tobacco product applications received since spring 2020, with a majority being for electronic cigarette products. Thus far, the FDA has completed reviews for 99% of these products.


Dr. Matthew Farrelly, director of the Office of Science at the FDA's Center for Tobacco Products (CTP), stated that...


Science is the cornerstone of the FDA's tobacco product review process. Today's decision to reject nearly 6,500 products was based on a lack of scientific evidence in the applications. We will continue to ensure that all new tobacco products undergo rigorous, scientific pre-market evaluations to determine whether they meet appropriate public health standards for legal marketing.


The FDA evaluates PMTAs based on public health standards, taking into account the risks and benefits to the entire population. When reviewing PMTAs for these companies, the premise is whether the products have additional advantages for adult smokers compared to tobacco flavors.


However, the evidence submitted by these applicants was insufficient to prove the existence of such advantages, hence they have received a marketing rejection order.


Brian King, the director of CTP, stated:


The applicant is responsible for providing sufficient scientific evidence to demonstrate that the introduction of a new tobacco product to the market meets the requirements for public health protection. To date, including the product in question, no flavored electronic cigarette products have met the standard for scientific adequacy. However, if the applicant meets this standard, the FDA will approve the product.


The companies that have obtained a marketing rejection order include:


Imperial Vapors LLC, Savage Enterprises, Big Time Vapes, SWT Global Supply Inc., Great Lakes Vapor, DNA Enterprise LLC doing business as Mech Sauce, and Absolute Vapor Inc., and ECBlend LLC are among the companies in the vaping industry. However, two other companies' names are not being disclosed by the FDA in order to protect potential commercial confidential information (CCI).


The FDA is committed to ensuring that all members of the industry, including manufacturers, importers, distributors and retailers, comply with the law.


Tobacco products that have been denied approval are prohibited from being sold, distributed, or marketed in the United States. They cannot be introduced or placed in interstate commerce, and if the product is already on the market, it must be removed or face enforcement action.


Reference:


The Food and Drug Administration (FDA) has issued orders denying marketing requests for around 6,500 flavored e-cigarette products.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reuters Tracks Big Tobacco’s Shift Beyond Cigarettes as Nicotine Pouches Vie for the Next Growth Curve
Reuters Tracks Big Tobacco’s Shift Beyond Cigarettes as Nicotine Pouches Vie for the Next Growth Curve
As cigarette markets face long-term pressure, major tobacco companies are increasingly turning to nicotine pouches in search of growth beyond combustible tobacco. Reuters has examined whether nicotine pouches can become the next strategic growth platform for companies including Philip Morris International, British American Tobacco and Japan Tobacco. PMI strengthened its position through the acquisition of Swedish Match and its ZYN brand, while BAT and JTI continue expanding their own nicotine pouch portfolios. The category has gained attention because of its smoke-free, device-free format, but regulation, youth-use concerns and market scale will determine whether it can become a long-term growth engine.
Regulations
Aug.18 by 2Firsts Perspectives
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Iowa Enforces Vape Registry Law as Retailers Warn Product Limits Could Increase Store Pressure
Iowa Enforces Vape Registry Law as Retailers Warn Product Limits Could Increase Store Pressure
Iowa has begun enforcing its vape registry law, requiring vape products to be registered before they can be legally sold in the state. The move follows a decision by the U.S. Court of Appeals for the Eighth Circuit to lift an injunction that had blocked enforcement. Retailers have warned that tighter product availability rules could increase pressure on vape shops. One Iowa retailer said that if only a limited number of products remain available, many stores could face significant business challenges.
Aug.06
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
China Tobacco International (HK) reported a 26.9% revenue decline in H1 2026, while gross profit fell only 9.5%, revealing sharp divergence across its businesses. Tobacco leaf imports contracted, while leaf exports and Brazil operations expanded strongly. Cigarette exports faced China duty-free market transition, and new tobacco products remained small. Meanwhile, CTIHK continues to strengthen its role as an investment and financing platform, though major external deals have yet to emerge. 2Firsts examines what these shifts mean for its next growth drivers.
Capital Markets
Aug.24